Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 5/20 | 0.39 |
| ▸ | EGFR | P00533 | 5/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.38 |
| ▸ | RET | P07949 | 7/20 | 0.37 |
| ▸ | KDR | P35968 | 7/20 | 0.37 |
| ▸ | KIF5B | P33176 | 6/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19645708 | 0.80 | RET (0.42) | SRCEGFRERBB2RETKDR | |
| SCHEMBL31554502 | 0.78 | RET (0.45) | SRCEGFRRETKDRKIF5B | |
| SCHEMBL29612554 | 0.78 | SRC (0.55) | SRCEGFRERBB2MAP2K1 | |
| SCHEMBL1898838 | 0.78 | SRC (0.55) | SRCEGFRERBB2MAP2K1 | |
| SCHEMBL5465970 | 0.75 | SRC (0.44) | SRCEGFRMAP2K1 | |
| SCHEMBL5452461 | 0.75 | EGFR (0.49) | SRCEGFRKDRMAP2K1CSF1R | |
| SCHEMBL5929884 | 0.74 | CSF1R (0.56) | CSF1R | |
| SCHEMBL4950543 | 0.72 | SRC (0.55) | SRCEGFRERBB2MAP2K1 | |
| SCHEMBL296984 | 0.70 | ENPP1 (0.63) | EGFRRETKDRKIF5B | |
| SCHEMBL30054610 | 0.70 | ENPP1 (0.63) | EGFRRETKDRKIF5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208164-A1 | Methods of synthesizing radiolabeled 3-cyano[14C]quinolines | WYETH (US) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208164-A1 | Methods of synthesizing radiolabeled 3-cyano[14C]quinolines | QPCT, RECQL, CBR3 | SRC 3839/4885EGFR 2355/4885ERBB2 2598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.